Steffi Oesterreich and Adrian V. Lee, breast cancer researchers at UPMC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, professor of radiology at UPMC Magee-Womens Hospital—all from the University of Pittsburgh School of Medicine—received funding from the Breast Cancer Research Foundation.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
